GTC Biotherapeutics (fka GTCB)

[DewDiligence]

Re: Moderate vs severe sepsis

Thanks for your post. The takeaway message here is that antithrombin works best in DIC/sepsis patients with moderate disease; in severe sepsis, patients are generally too ill for any treatment to be effective.

In Leo’s phase-2 trial, eligibility is restricted to patients whose predicted mortality—based on an industry-standard model—is between 30% and 60% (i.e. predicted survival of 40-70%): #msg-21636676. This is a very important feature of the trial that has often been overlooked. Regards, Dew